INM vs. ATNF, PRFX, NBSE, ALLR, QLGN, PXMD, LSDI, PBLA, BDRX, and GRI
Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include 180 Life Sciences (ATNF), PainReform (PRFX), NeuBase Therapeutics (NBSE), Allarity Therapeutics (ALLR), Qualigen Therapeutics (QLGN), PaxMedica (PXMD), Lucy Scientific Discovery (LSDI), Panbela Therapeutics (PBLA), Biodexa Pharmaceuticals (BDRX), and GRI Bio (GRI). These companies are all part of the "pharmaceutical preparations" industry.
180 Life Sciences (NASDAQ:ATNF) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
In the previous week, 180 Life Sciences had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for 180 Life Sciences and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.91 beat 180 Life Sciences' score of 0.44 indicating that 180 Life Sciences is being referred to more favorably in the media.
4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 4.1% of 180 Life Sciences shares are owned by insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
InMed Pharmaceuticals received 6 more outperform votes than 180 Life Sciences when rated by MarketBeat users. However, 66.67% of users gave 180 Life Sciences an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.
InMed Pharmaceuticals has higher revenue and earnings than 180 Life Sciences.
180 Life Sciences has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500.
180 Life Sciences has a net margin of 0.00% compared to 180 Life Sciences' net margin of -115.76%. 180 Life Sciences' return on equity of -54.31% beat InMed Pharmaceuticals' return on equity.
Summary
180 Life Sciences and InMed Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get InMed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InMed Pharmaceuticals Competitors List
Related Companies and Tools
